|Day Low/High||165.29 / 166.91|
|52 Wk Low/High||109.16 / 165.16|
Today's market has ignored disappointing profit results at 3M (down $3), Johnson & Johnson (down $3) and Verizon (down $2.50), among others. The "reflation" trade appears to be back (in part a function of several predictable executive orders by ...
Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.
Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.
The following companies (hat tip Zero Hedge) missed on the top line (sales) this morning (profits weren't much better): Johnson & Johnson MMM DuPont Kimberly-Clark Verizon Again, for emphasis -- beware of the bullish narrative of an improving profit...
Dow Jones Industrial Average member Johnson & Johnson is lower in pre-market trading. The reason? The drug maker took a page out of IBM's playbook by recording a much lower effective tax rate in the quarter (14.5% vs. 18%), which on an adjusted basi...
On Tuesday, January 24, investors await a host of quarterly earnings reports.
For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
After an up-and-down year, this household name is as strong as ever.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
We toured the company helping design cool workspaces for Fortune 500 companies like Facebook and Microsoft.
Shares of Johnson & Johnson are poised for a rally as the stock is currently trading about 8% off its 52-week high.
Johnson & Johnson could repatriate offshore profits in 2017 if a potential tax holiday is passed.
Animal health and oncology deal activity is heating up in 2017.
After a period of consolidation, several personal care products companies look like they are about to rally.
Disney and Goldman are doing a lot of the heavy lifting.
A big damage award against J&J has been reduced by a judge, but the company is still facing thousands of additional claims.
There may be some diamonds-in-the-rough among pharmaceutical consolidators and hospital chains.
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
Jim Cramer wonders whether someone at Johnson & Johnson is now willing to pay more for Actelion, or if there was more give from the other side.
This is what you need to know before the opening bell on Thursday.
The Fed seems to have aligned itself with the new emerging themes of financials and small-caps.
Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.
The markets moved lower from the "get go," though about the time Sixty Minutes was on last evening the S&P 500 futures were up 10 handles. (Futures closed down 2.5 handles) Perhaps this is the start of a well due correction. Apropos, here is the q...
It's simply a little consolidation after a huge run. But could it develop?
There's a striking lack of volatility, and that's a flashing red warning signal.
But who are these buyers? Where are the sellers?
Jim Cramer is watching Johnson & Johnson, which may buy a Swiss drugmaker. Cramer says it's important to see how the deal is structured.